Kura Oncology (KURA) stock slid 7% in post-market trading after the company issued an update on its drug ziftomenib.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback